MediSense's automated glucose monitor gets FDA OK
This article was originally published in Clinica
Abbott's MediSense subsidiary has received approval from the US FDA to market its Sof-Tact diabetes management system, which incorporates a vacuum-seal device that allows users to draw blood samples from parts of the body other than the pain-sensitive fingertips. Abbott claims the system is the first automated glucose monitor to offer lancing, blood collection and glucose measurement with a single press of a button. Furthermore, it incorporates new strip technology that requires less blood than conventional tests.